CVS Health (CVS) Stock Forecast & Price Target

$65.46

+0.21 (+0.32%)

(As of 09:46 AM ET)

CVS Health - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 21 Analyst Ratings

Sell
0

Hold
9

Buy
12

Based on 21 Wall Street analysts who have issued ratings for CVS Health in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 21 analysts, 9 have given a hold rating, and 12 have given a buy rating for CVS.

Consensus Price Target

$73.40
12.47% Upside

According to the 21 analysts' twelve-month price targets for CVS Health, the average price target is $73.40. The highest price target for CVS is $100.00, while the lowest price target for CVS is $60.00. The average price target represents a forecasted upside of 12.47% from the current price of $65.46.

Get the Latest News and Ratings for CVS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for CVS Health and its competitors.

CVS Analyst Ratings Over Time

Type	Current Forecast 10/9/23 to 10/8/24	1 Month Ago 9/9/23 to 9/8/24	3 Months Ago 7/11/23 to 7/10/24	1 Year Ago 10/9/22 to 10/9/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	12 Buy rating(s)	12 Buy rating(s)	13 Buy rating(s)	14 Buy rating(s)
Hold	9 Hold rating(s)	10 Hold rating(s)	10 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$73.40	$72.48	$75.05	$95.28
Forecasted Upside	12.47% Upside	25.50% Upside	30.47% Upside	33.72% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Don't Pay a Dime for Marc Lichtenfeld's Top AI Picks (Ad)

Usually, you'd have to plunk down a hefty sum to get your hands on Marc Lichtenfeld's latest income research... But today, the author of Get Rich with Dividends is feeling extra generous...

Click here now to claim your FREE copy of Marc's AI playbook.

CVS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CVS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

CVS Health Stock vs. The Competition

Type	CVS Health	Retail/Wholesale Companies	S&P 500
Consensus Rating Score	2.57	2.51	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	12.47% Upside	41.50% Upside	8.03% Upside
News Sentiment Rating	Neutral News See Recent CVS News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/4/2024	TD Cowen 4 of 5 stars	C. Rhyee Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$59.00 ➝ $85.00	+35.09%
10/1/2024	Cantor Fitzgerald 3 of 5 stars	S. James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$62.00 ➝ $62.00	+0.27%
9/4/2024	Royal Bank of Canada 4 of 5 stars		Reiterated Rating	Outperform ➝ Outperform	$68.00 ➝ $68.00	+17.22%
8/12/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$60.00 ➝ $61.00	+8.04%
8/9/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold ➝ Hold	$64.00 ➝ $63.00	+10.24%
8/8/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$65.00 ➝ $63.00	+8.85%
Get the Latest News and Ratings for CVS and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for CVS Health and its competitors with MarketBeat's FREE daily newsletter.
8/8/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$65.00 ➝ $62.00	+9.79%
5/30/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Ha Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
5/30/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$101.00 ➝ $86.00	+53.54%
5/30/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral	$61.00	+13.55%
5/8/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Graja Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$100.00 ➝ $80.00	+44.85%
5/2/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$95.00 ➝ $77.00	+41.73%
5/2/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$85.00 ➝ $74.00	+36.08%
5/2/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$90.00 ➝ $66.00	+21.37%
5/2/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$86.00 ➝ $72.00	+27.84%
5/2/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$85.00 ➝ $60.00	+6.53%
5/1/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Cherny Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
5/1/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Market Perform	$87.00 ➝ $60.00	+5.60%
3/15/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$93.00 ➝ $94.00	+21.75%
12/22/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$94.00	+19.56%
11/2/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$110.00 ➝ $100.00	+43.55%
10/10/2023	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$93.00 ➝ $80.00	+11.41%
9/12/2023	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Peer Perform ➝ Outperform	$80.00	+16.36%
8/17/2023	Edward Jones Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
8/4/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$90.00 ➝ $85.00	+14.34%
5/8/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$125.00 ➝ $96.00	+35.82%
2/9/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$130.00 ➝ $143.00	+60.75%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 10:07 AM ET.

Should I Buy CVS Health Stock? CVS Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, September 30, 2024. Please send any questions or comments about these CVS Health pros and cons to contact@marketbeat.com.

CVS Health
Bull Case

Here are some ways that investors could benefit from investing in CVS Health Co.:

CVS Health Co. stock price is currently at an attractive level, providing a potential buying opportunity for investors.
CVS Health Co. has a consistent track record of paying dividends, offering investors a source of regular income.
CVS Health Co. has a diversified business model operating in Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments, reducing risk exposure.
CVS Health Co. reported strong quarterly earnings, beating analysts' estimates, indicating a healthy financial performance.
CVS Health Co. has a relatively low price-to-earnings ratio of 10.26, suggesting the stock may be undervalued compared to industry peers.

CVS Health
Bear Case

Investors should be bearish about investing in CVS Health Co. for these reasons:

Market analysts have mixed ratings on CVS Health Co., with some suggesting a "hold" stance, indicating uncertainty in the stock's future performance.
CVS Health Co. faces competition in the healthcare industry, which could impact its market share and profitability.
The company's revenue growth rate has been modest, raising concerns about its ability to drive significant top-line expansion.
CVS Health Co. operates in a highly regulated industry, subject to changes in healthcare policies and regulations that could affect its operations.
The stock's 52-week high of $83.25 indicates potential volatility in its price movements, posing a risk for investors seeking stability.

CVS Forecast - Frequently Asked Questions

: According to the research reports of 21 Wall Street equities research analysts, the average twelve-month stock price forecast for CVS Health is $73.40, with a high forecast of $100.00 and a low forecast of $60.00.
: 21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CVS Health in the last twelve months. There are currently 9 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CVS shares.
: According to analysts, CVS Health's stock has a predicted upside of 12.13% based on their 12-month stock forecasts.
: Over the previous 90 days, CVS Health's stock had 1 upgrade by analysts.
: CVS Health has been rated by research analysts at Barclays, Cantor Fitzgerald, Deutsche Bank Aktiengesellschaft, Evercore ISI, Royal Bank of Canada, TD Cowen, and Wells Fargo & Company in the past 90 days.
: Analysts like CVS Health more than other "retail/wholesale" companies. The consensus rating score for CVS Health is 2.57 while the average consensus rating score for "retail/wholesale" companies is 2.51. Learn more on how CVS compares to other companies.

Stock Forecasts and Research Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

The most important AI company you've never heard of (Ad)

Because this small company solves the BIGGEST problem with Nvidia's AI chips. Already, Amazon, Microsoft, Google and others are lining up to get this company's products.

Get the full story on this secret AI company poised for massive growth

This page (NYSE:CVS) was last updated on 10/8/2024 by MarketBeat.com Staff

From Our Partners